ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) Files An 8-K Results of Operations and Financial Condition

Item 2.02

On May 9, 2017, Albany Molecular Research, Inc. (the Company)
issued a press release announcing its financial results for the
first quarter ended March 31, 2017. That release referred to
certain attached financial highlights for the first quarter ended
March 31, 2017. The full text of the press release, including the
financial tables referred to within the release, which were
posted on the Companys internet website, is furnished in Exhibit
99.1 hereto and is incorporated by reference herein.

About ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI)

Albany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) Recent Trading Information

ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) closed its last trading session up +1.98 at 18.00 with 2,354,329 shares trading hands.